Our medical pipeline includes 3 new neurostimulation devices to modulate the activity of vagus, trigeminal and occipital nerves, combining electrical, mechanical, and ultrasound stimulation.

These new technologies will be developed and clinically validated to treat mental, neurological, and cardiological diseases.

REMO is a stimulator of both the trigeminal and occipital nerves that is intended to be a game-changer for treating chronic pain associated with a multitude of pathologies that, for the most part, are not well treated.

Misused the current pharmacologic strategies such as Opioids are responsible for a global pandemic generating severe side effects and an enormous economic burden.

REMO will help clinicians to relieve the pain in an efficient and safe manner, helping people all around the world to improve their lives.

DEVA will be the most efficacy vagus nerve stimulator existing in the market.

Our technical and clinical team is working on the development of a bilateral stimulator of the vagus nerve to modulate the hyperactivity of the sympathetic nervous system which is underlying most psychiatric diseases.

Moreover, our stimulator may be combined with parametrizable virtual reality psychotherapy to treat anxiety and stress-related disorders such as Post-Traumatic Stress Disorder.


HATY is a vagus nerve stimulator to treat cardiological conditions such as heart failure and arrhythmia.

Currently, we are executing a 4 years longitudinal clinical trial to evaluate the impact of the modulation of the neurovegetative response to alleviate cardiac failure in emergency patients.

At the same time, we are validating a cardiological wearable system to help cardiologists to improve the diagnostic and management of these pathologies.